Michigan House Bill HB5162

Michigan 2025-2026 Regular Session

• Introduced: 10/29/25
• Refer: 10/29/25
• Report Pass: 12/10/25
• Engrossed: 3/4/26
• Refer: 3/10/26

Caption

Controlled substances: schedules; scheduling of certain controlled substances; modify. Amends sec. 7204 of 1978 PA 368 (MCL 333.7204).

Impact

The proposed changes will directly impact how controlled substances are handled under Michigan’s public health regulations. By requiring an administrative meeting to contest the scheduling of newly designated controlled substances, this bill could lead to more timely responses and consistency in the application of drug regulations. Stakeholders in the healthcare system, including healthcare providers and law enforcement, may be affected by these regulatory changes as they seek to maintain compliance with state laws in line with federal requirements.

Summary

House Bill 5162 aims to amend section 7204 of the Public Health Code in Michigan, which relates to the scheduling of controlled substances. This bill seeks to establish a more consistent administrative process for the scheduling of substances that are either designated, rescheduled, or deleted under federal law. It empowers the state’s administrator to determine whether such substances should be similarly controlled under state law unless a board meeting is convened within a specified timeframe. The bill reflects an effort to streamline the scheduling process and ensure that state law is in alignment with federal designations, promoting public health and safety.

Sentiment

The sentiment around HB 5162 appears to be generally supportive among legislators focused on public health issues, with a recognition of the importance of keeping state regulations in sync with federal rules. However, there can be concerns about the potential for bureaucratic delays if the administrator does not act swiftly, which might impede timely interventions for substance control. The bill is anticipated to promote a more cohesive approach to managing public health regarding controlled substances, but discussions around its implementation could highlight differing viewpoints on regulatory efficiency versus necessary oversight.

Contention

Notable points of contention surrounding HB 5162 may include debates on the balance of authority between state and federal regulations regarding controlled substances. While some argue that the bill facilitates better alignment and responsiveness to federal changes, others may express concerns about the implications for state autonomy in regulating drug policies. The need for transparency and accountability in the decision-making process of the administrator could also be a focal point in discussions as legislators evaluate the breadth of authority proposed under this bill.